Miflonide Breezhaler (Budesonide)

Budesonide, the active ingredient in Miflonide Breezhaler, is a corticosteroid presented as a dry powder inhaler for inhalation use. It reduces airway inflammation and is indicated for the long‑term management of asthma and chronic obstructive pulmonary disease (COPD) in adults and children.

GNH USA supplies Miflonide Breezhaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Clients benefit from consistent product availability and regulatory support across multiple markets.

Miflonide Breezhaler (budesonide) is a corticosteroid inhaler that targets inflammatory airway diseases.

- Asthma: improves symptom control and reduces frequency of exacerbations. - Chronic obstructive pulmonary disease (COPD): decreases breathlessness and lowers risk of flare‑ups. - Bronchial hyperresponsiveness: helps reduce airway hyperreactivity in patients with variable airflow limitation.

Inhaled budesonide may cause a range of adverse reactions, most of which are mild and localized to the respiratory tract.

Common Side Effects: - Oral candidiasis: fungal infection of the mouth. - Hoarseness: voice changes after inhalation. - Throat irritation: mild discomfort or soreness. - Cough: transient irritation during use. - Headache: occasional mild headache. - Dysphonia: altered vocal quality.

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of breathing. - Adrenal suppression: reduced endogenous cortisol production with long‑term high doses. - Pneumonia: increased risk of lower respiratory tract infection. - Severe allergic reaction: anaphylaxis or angioedema. - Growth suppression in children: potential impact on height development. - Immunosuppression: heightened susceptibility to infections.

Before prescribing Miflonide Breezhaler, clinicians should consider several safety precautions to minimize risk.

- Infection risk: assess for active respiratory infections before initiating therapy. - Oral hygiene: advise patients to rinse mouth after each inhalation to reduce candidiasis. - Adrenal function: monitor for signs of adrenal insufficiency during prolonged high‑dose use. - Tuberculosis: use with caution in patients with active or latent TB. - Discontinuation: avoid abrupt cessation after long‑term therapy; taper if clinically indicated. - Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Budesonide inhalation can interact with other medicines that affect its metabolism or immunosuppressive activity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): may increase systemic budesonide exposure. - Systemic immunosuppressants (e.g., azathioprine, cyclosporine): additive immunosuppression risk.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole): may modestly raise budesonide levels. - Antifungal azoles (e.g., itraconazole): require monitoring for adrenal effects. - Phenobarbital or rifampicin: may reduce budesonide efficacy by inducing metabolism.